10:03 AM EST - Prometic Life Sciences Inc. : Has received Swedish Medical Products Agency Clinical Trial Application approval to commence a clinical trial of its plasminogen therapy in patients suffering from chronic tympanic membrane perforation (chronic TMP). Prometic Life Sciences Inc.
shares T.PLI are trading down $0.04 at $1.33.
